Efficacy and Safety of Hizikia Fusiformis Extract in Subjects Showing Erosive Gastritis
NCT ID: NCT01689701
Last Updated: 2019-09-20
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
54 participants
INTERVENTIONAL
2011-08-31
2012-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effact of Helicobacter Hylori Eradication on the Development of Gastric Mucosa Pathology
NCT04029441
Fuzheng Nizeng Formula for Chronic Atrophic Gastritis With Low-grade Intraepithelial Neoplasia, a Multicenter Randomized Controlled Trial
NCT06324825
Phase II Study to Evaluate the Efficacy and Safety of GC6101A in Subjects With Gastritis
NCT02353039
Efficacy and Safety of Using Granules Dendrobii for the Treatment of Chronic Atrophic Gastritis
NCT05209633
Study to Assess the Efficacy and Safety of SK-MS10 in Subjects With Acute and Chronic Gastritis
NCT01578811
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Hizikia Fusiformis extract
Hizikia Fusiformis extract
Hizikia Fusiformis extract(1.3g/d)
Placebo
Placebo
Placebo(1.3g/d)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Hizikia Fusiformis extract
Hizikia Fusiformis extract(1.3g/d)
Placebo
Placebo(1.3g/d)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects Showing Erosive Gastritis (endoscopy)
* Able to give informed consent
Exclusion Criteria
* Allergic or hypersensitive to any of the ingredients in the test products
* History of disease that could interfere with the test products or impede their absorption, such as gastrointestinal disease or gastrointestinal surgery
* Taken antibiotics and stomach medicines such as steroid, bismuth compound and proton pump inhibitor within 1 months
* Participation in any other clinical trials within past 2 months
* Laboratory test, medical or psychological conditions deemed by the investigators to interfere with successful participation in the study
* Pregnant or lactating women etc.
19 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chonbuk National University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Soo-Wan Chae
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sang-Wook Kim, MD
Role: PRINCIPAL_INVESTIGATOR
Chonbuk National University Hospital
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PKU-EG-ECKL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.